BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer

  Philip Kantoff, CEO of Convergent Therapeutics, spoke to BioSpace before the American Association for Cancer Research Annual Meeting on April 8-13 about CONV01-α.

  April 14, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Research Roundup: A Potential Treatment for Metabolic Syndrome and Affimed’s NK Combo

  Typical metabolic syndrome treatment includes a healthy diet, exercise, and possibly metformin, but soon, there may be a new treatment. For that and more research news, continue reading.

  April 14, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Protagonist’s PV Breakthrough Designation on the Line

  Protagonist disclosed the FDA issued a letter of intent to rescind the status for rusfertide based on concerns first raised in a clinical hold placed on the drug.

  April 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Mayo Researchers Combine CAR-T and Oncolytic Virus in New Attack on Cancer

  Researchers are combining CAR-T cell therapy with cancer-killing viruses to create an even more potent treatment against solid cancer tumors.

  April 14, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Sanofi, AbbVie and Genmab Celebrate Mid-Phase Trial Wins

  AbbVie and Genmab announced positive topline results from their Phase I/II trial for lymphoma treatment; Sanofi posted positive results from its Phase I/II trial for the treatment of ITP.

  April 14, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Be Bio Scores $130M for New Class of Cellular Medicine

  Be Biopharma closed a massive $130M financing to further its proprietary autologous and allogeneic BeCM platform and discover therapies for cancer, rare diseases and more.

  April 14, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  BioSpace Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena Oncology

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

  April 14, 2022

   · 

  8 min read

   · 

  Alex Keown
• 

  FDA

  FDA Issues New Guidance to Increase Minority Representation in Clinical Trials

  The FDA issued new guidance urging drugmakers to submit racial and minority recruitment plans when designing their studies.

  April 14, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Highlights from AACR’s Final Day: Mustang Bio, ChemoCentryx, Allogene and More

  The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.

  April 14, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Drug Price Watchdog Calls Bluebird Bio’s $2.1 Million Gene Therapy Cost-Effective

  Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy’s cost-effectiveness.

  April 14, 2022

   · 

  4 min read

   · 

  Mark Terry